Latest News and Press Releases

‘1104 sublingual formulation achieved extensive systemic exposure and demonstrated impact across measures of disease in additional preclinical studies in atopic dermatitis Sublingual formulation and...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present two posters on its lead candidate,...

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV)In multiple preclinical models evaluated...

Sublingual (SL) formulation of ‘1104 achieved comparable responses to subcutaneous (SQ) and intravenous (IV) injections‘1104 SC and SL dosing options create opportunities for highly differentiated...

Data continues to differentiate ‘1104 as a potential allergic disease treatment that acts upstream in the immune cascade‘1104 reduces key indices of skin inflammation and inflammatory mediators in a...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that President and Chief Executive Officer, Woody Bryan,...

Reduction of key proteins in the interleukin 4 (IL-4) and IL-13 signalling pathway via SHP-1 activation is a key component involved in the mechanism of action of ‘1104First-in-class upstream approach...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...

- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo...